Satellite Symposium

Eli Lilly

Thursday, September 2nd, 12:00 - 13:00

“Unmet needs in Rheumatology- what we can do about it”

Till Uhlig (Moderator)                            Introduction (5 mins) 

RA and pain                                                                        Peter Taylor                                                  “Alleviating pain; the physician’s, or the patient’s?!" (20 mins)

PsA SPIRIT H2H                                                       Lars Erik Kristensen                                            "TNF vs IL-17: bring on the H2H data in PsA!" (20 mins)

Live Q&A (moderator + speakers) (15 mins) 

Image

Novartis

Friday, September 3rd, 12:00 - 13:00

Axial psoriatic arthritis – does it differ from other forms of axial SpA?

Senior Professor Lennart Jacobsson                Sahlgrenska Akademin                        Gothenburg, Sweden

Image

Boehringer Ingelheim

Friday, September 3rd, 12:00 - 13:00

Interstitial lung disease in patients with auto-immune diseases. What is around the corner? 

Anna Maria Hoffmann-Vold (Chair) (5 min)   The lung in CTD-ILD – silent foe

Oliver Distler (20 min                          Immunomodulation and fibrosis inhibition in the treatment of SSc-ILD

Kevin Brown (20 min                                                 CTD-ILD – new options for management


Anna Maria Hoffmann-Vold (15 min)                panel debate, Q&A, wrap up

Image

Abbvie

Friday, September 3rd, 08:15 – 09:15

Meeting room: Polarbjørn

The role of JAKi in RA- how do patients respond to ▼RINVOQ®(upadacitinib)

Dr. Guro Goll (Chair and introduction)

Prof. Peter Taylor                                                            The role of JAKi in RA and RINVOQ data in RA

Dr. Guro Goll, Prof. Peter Taylor and              Dr. Joonas Rautavaara                                    Panel Discussion                                                            Highlights from the EULAR recommendations regarding JAKi                    Patient case, sharing own experience                Discussion                                                                      Q&A and close 

Image

Abbvie

Saturday, September 4th, 08:00 – 09:00

Meeting room: Polarbjørn

The role of JAKi in PsA and AS- the efficacy and safety of ▼RINVOQ® (upadacitinib)

Topic Presenter/Moderator Chair and Introduction Dr. Lars-Erik Kristensen, Denmark

The role of JAKi in SpA and RINVOQ data on PsA/AS. Dr. Xenofon Baraliakos, Germany

Panel Discussion: EULAR Recommendations for management of PsA and ASAC/EULAR Recommendations

Discussion Dr. Lars-Erik Kristensen and Dr. Xenofon Baraliakos

Q&A and close All

Image